Innate Pharma SA Class A
No trades
No trades
Price target
5.970.000.00%
The 5 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 5 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
The current price of IPH is 1.805 EUR — it has decreased by −15.16% in the past 24 hours. Watch Innate Pharma SA Class A stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange Innate Pharma SA Class A stocks are traded under the ticker IPH.
IPH stock has risen by 21.92% compared to the previous week, the month change is a 17.89% rise, over the last year Innate Pharma SA Class A has showed a −6.91% decrease.
We've gathered analysts' opinions on Innate Pharma SA Class A future price: according to them, IPH price has a max estimate of 7.79 EUR and a min estimate of 3.46 EUR. Watch IPH chart and read a more detailed Innate Pharma SA Class A stock forecast: see what analysts think of Innate Pharma SA Class A and suggest that you do with its stocks.
IPH stock is 7.42% volatile and has beta coefficient of 1.10. Track Innate Pharma SA Class A stock price on the chart and check out the list of the most volatile stocks — is Innate Pharma SA Class A there?
Today Innate Pharma SA Class A has the market capitalization of 174.75 M, it has increased by 2.43% over the last week.
Yes, you can track Innate Pharma SA Class A financials in yearly and quarterly reports right on TradingView.
Innate Pharma SA Class A is going to release the next earnings report on Sep 17, 2026. Keep track of upcoming events with our Earnings Calendar.
IPH earnings for the last half-year are −0.30 EUR per share, whereas the estimation was −0.30 EUR, resulting in a 0.00% surprise. The estimated earnings for the next half-year are −0.30 EUR per share. See more details about Innate Pharma SA Class A earnings.
Innate Pharma SA Class A revenue for the last half-year amounts to 4.14 M EUR, despite the estimated figure of 4.90 M EUR. In the next half-year revenue is expected to reach 5.03 M EUR.
IPH net income for the last half-year is −27.83 M EUR, while the previous report showed −21.34 M EUR of net income which accounts for 0.00% change. Track more Innate Pharma SA Class A financial stats to get the full picture.
No, IPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 17, 2026, the company has 163 employees. See our rating of the largest employees — is Innate Pharma SA Class A on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Innate Pharma SA Class A EBITDA is −58.86 M EUR, and current EBITDA margin is −2.01 K%. See more stats in Innate Pharma SA Class A financial statements.
Like other stocks, IPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Innate Pharma SA Class A stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Innate Pharma SA Class A technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Innate Pharma SA Class A stock shows the neutral signal. See more of Innate Pharma SA Class A technicals for a more comprehensive analysis.